Intranasal immunization of mice with PspA (Pneumococcal surface protein A) can prevent lntranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 839-846

  Wu, Hong Yin ^b   Nahm, Moon H ^b   Guo, Y ^b   Russell, Michael W ^b   Briles, David E ^a  

^a University of Alabama at Birmingham   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; PROTEIN A; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; IMMUNIZATION; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0030934988     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513980     Document Type: Article

References (9)

1. McGhee JR, Mestecky J. In defense of mucosal surfaces. Development of novel vaccines for IgA responses at the portals of entry of microbial pathogens. Infect Dis Clinics N Am 1990;4:315-41.
2. Mestecky J, McGhee JR. Prospects for human mucosal vaccines. In: Ciardi J, McGhee JR, Keith J, eds. Genetically engineered vaccines. New York: Plenum Press, 1992:13-23.
3. Fraser DW. What are our bacterial disease problems? In: Robbins JB, Hill JC, Sadoff JC, Weinstein L, eds. Bacterial vaccines. New York: Thieme Medical, 1982:xix-xxiv.
4. Jernigan DB, Cetron MS, Breiman RF. Defining the public health impact of drug resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep 1996;45:1-20.
5. Schwartz B, Gove S, Lob-Lovit J, Kirkwood BR. Potential interactions for the prevention of childhood pneumonia in developing countries: etiology of accute lower respiratory infections among young children in developing countries. Pediatr Infect Dis (in press).
6. Wood WB, Smith MR. The inhibition of surface phagocytosis by the capsular "slime layer" of pneumococcus type III. J Exp Med 1949;90: 85-99.
7. Kelly T, Dillard JP, Yother J. Effect of genetic switching of capsule type on virulence of Streptococcus pneumoniae. Infect Immun 1994; 62:1813-9.
8. McDaniel LS, Yother J, Vijayakumar M, McGarry L, Guild WR, Briles DE. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987; 165:381-94.
9. Shapiro ED, Berg AT, Austrian R, et al. Protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.